A Chinese flag is displayed next to a “Made in China” sign seen on a printed circuit board with semiconductor chips, in this illustration picture taken February 17, 2023.
Florence Lo | Reuters
China could face more semiconductor export curbs from the likes of the U.S. and the Netherlands to contain the Asian powerhouse’s chip tech, analysts told CNBC.
Earlier this year, the Netherlands blocked Dutch semiconductor equipment maker ASML from exporting some of its deep ultraviolet lithography systems to China. ASML sells lithography machines that are key to manufacturing advanced chips.
It came after the U.S. tightened export controls on advanced semiconductors and chipmaking tools to China in October last year, building on previous rules. Washington is concerned that Beijing could use these advanced chips in artificial intelligence and military applications.
“I wouldn’t be surprised if there’s more [U.S. restrictions] coming just because we’re still in the middle of this tit-for-tat. And there’s a lot of hawks in the U.S. that are really concerned about China’s military buildup,” said Dan Hutcheson, vice chair and senior research fellow at TechInsights, on CNBC’s “Squawk Box Asia” Tuesday.
China’s Ministry of Commerce said last week that the U.S. is weaponizing export controls as a tool, adding that it is “highly concerned about the U.S.’s direct intervention” in the issue of high-tech exports by Dutch companies to China.
“It’s further evidence that not just the U.S. government, but also other Western countries like the Dutch government, are going to keep ratcheting up some of the restrictions that we’ve seen around both chipmaking equipment and also advanced semiconductors,” Chris Miller, author of “Chip War” told CNBC’s “Squawk Box Asia” in early January.
Nvidia’s less powerful A800 and H800 chips were developed after the U.S. government banned shipments of the A100 and H100 chips — which are advanced graphics processing units sold to businesses — to China in August 2022.
With [U.S.] elections impending and political tension continuing to exist in the Taiwan Strait, it’s hard to envision a meaningful pull back on restrictions. If anything, I see further tightening.
“The U.S. government has signaled that they’re planning to roll out new export controls that do close loopholes on a regular basis,” said Miller.
China’s imports of integrated circuits in 2023 plunged amid U.S. curbs, falling 15.4% year-on-year to $349.4 billion in 2023, according to customs data released on Friday (Jan. 12). Shipment volume also declined by 10.8%, the data showed.
“With [U.S.] elections impending and political tension continuing to exist in the Taiwan Strait, it’s hard to envision a meaningful pull back on restrictions. If anything, I see further tightening,” Daniel Newman, principal analyst at Futurum Research, told CNBC last week.
China opposes Taiwan independence and has urged the U.S. to “stop arming Taiwan,” according to a readout on Jan. 10.
Since 2019, the U.S. has slapped sanctions on Chinese tech firms such as Huawei and China’s largest chipmaker SMIC, forcing Beijing to boost its domestic industry.
Revenue of China’s top 10 chip-equipment makers surged 39% in the first half of 2023 compared to a year earlier, according to Shanghai-based CINNO Research.
“I do think the short-term provides an advantage to the West, but China will do everything in its power to be sure it isn’t left out of the chip race,” said Futurum’s Newman.
China has traditionally been dependent on foreign firms for critical components.
After the Dutch government revoked the export license of ASML, Beijing no longer has access to some of the most advanced chipmaking tools in the world.
China has also been barred from importing ASML’s extreme ultraviolet lithography machines, which companies like Taiwan’s TSMC need to make the smallest and most sophisticated chips.
Bitcoin briefly dropped below the $90,000 mark on Monday, extending its slide as investors continue to dump growth oriented assets like crypto and tech stocks.
The price of the flagship cryptocurrency was last lower by 3% at $91,358.66 to start the week, according to Coin Metrics. Earlier, it fell as low as $89,259.00. Bitcoin is down 10% in the past week.
Stock Chart IconStock chart icon
Bitcoin extends its slide as growth-oriented assets continue to get hit
“The need for liquidity is caused by FX spikes because of strong end-of-year U.S. economy number, the stock market rallying strong, and there are other places money is needed in the short-term,” said James Davies, co-founder and CEO at crypto trading platform Crypto Valley Exchange. “If we want bitcoin to act like a currency, we need to accept when it does, and this is one of those times. The U.S. Dollar has gotten stronger ad everything else including bitcoin is weaker when measured in dollars.”
Investor sentiment was optimistic coming into 2025, with markets looking forward to having a pro-crypto Congress and White House. That hope had outweighed any concern about macroeconomic-related speedbumps, until last week.
Investors are now warning that the first quarter of this year could be more turbulent for crypto than previously anticipated.
Bitcoin’s price grew 120% in 2024 but is down 3% so far in the new year.
Don’t miss these cryptocurrency insights from CNBC Pro:
Health-care payments company Waystar on Monday announced a new generative artificial intelligence tool that can help hospitals quickly tackle one of their most costly and tedious responsibilities: fighting insurance denials.
Hospitals and health systems spend nearly $20 billion a year trying to overturn denied claims, according to a March report from the group purchasing organization Premier.
“We think if we can develop software that makes people’s lives better in an otherwise stressful moment of time when they’re getting health-care, then we’re doing something good,” Waystar CEO Matt Hawkins told CNBC.
Waystar’s new solution, called AltitudeCreate, uses generative AI to automatically draft appeal letters. The company said the feature could help providers drive down costs and spare them the headache of digging through complex contracts and records to put the letters together manually.
Hawkins led Waystar through its initial public offering in June, where it raised around $1 billion. The company handled more than $1.2 trillion in gross claims volume in 2023, touching about 50% of patients in the U.S.
Claim denials have become a hot-button issue across the nation following the deadly shooting of UnitedHealthcare CEO Brian Thompson in December. Americans flooded social media with posts about their frustrations and resentment toward the insurance industry, often sharing stories about their own negative experiences.
Read more CNBC reporting on AI
When a patient receives medical care in the U.S., it kicks off a notoriously complex billing process. Providers like hospitals, health systems or ambulatory care facilities submit an invoice called a claim to an insurance company, and the insurer will approve or deny the claim based on whether or not it meets the company’s criteria for reimbursement.
If a claim is denied, patients are often responsible for covering the cost out-of-pocket. More than 450 million claims are denied each year, and denial rates are rising, Waystar said.
Providers can ask insurers to reevaluate claim denials by submitting an appeal letter, but drafting these letters is a time-consuming and expensive process that doesn’t guarantee a different outcome.
Hawkins said that while there’s been a lot of discussion around claims denials recently, AltitudeCreate has been in the works at Waystar for the last six to eight months. The company announced an AI-focused partnership with Google Cloud in May, and automating claims denials was one of the 12 use cases the companies planned to explore.
Waystar has also had a denial and appeal management software module available for several years, Hawkins added.
AltitudeCreate is one tool available within a broader suite of Waystar’s AI offerings called AltitudeAI, which the company also unveiled on Monday. AltitudeCreate rolled out to organizations that are already using Waystar’s denial and appeal management software modules earlier this month at no additional cost, the company said.
Waystar plans to make the feature more broadly available in the future.
“In the face of all of this administrative waste in health-care where provider organizations are understaffed and don’t have time to even follow up on a claim when it does get denied, we’re bringing software to bear that helps to automate that experience,” Hawkins said.
Through the collaboration, General Catalyst portfolio companies will use AWS’ services to build and roll out AI tools for health systems more quickly. Aidoc, which applies AI to medical imaging, and Commure, which automates provider workflows with AI, will be the first two companies to participate.
No financial terms were disclosed in the announcement.
“Without a strong partner like Amazon and AWS to stand alongside them, to co-develop and support these companies … it’s not going to move as fast as we hope,” Chris Bischoff, head of global health-care investing at General Catalyst, told CNBC in an interview.
Health systems are strained in the U.S., with staff burnout, growing labor shortages and razor-thin margins. These challenges often seem enticing for enterprising tech startups to tackle, especially as the multi-trillion dollar health-care industry dangles the prospect of large financial returns.
Hospitals operate in a complex, technology-weary and highly-regulated sector that can be difficult for startups to break into. General Catalyst is hoping to help its companies fast-track the development and go-to-market process by leveraging resources like computing power from AWS.
Read more CNBC reporting on AI
General Catalyst is no stranger to taking big swings in health-care.
The firm has closed more than 60 digital health deals since 2020, behind only Gaingels and Alumni Ventures, according to a December report from PitchBook. Last January, General Catalyst shocked the industry by announcing that its new business, the Health Assurance Transformation Company, planned to acquire an Ohio-based health system – an unprecedented move in venture capital.
General Catalyst’s “deep understanding” of health systems’ financial and operating realities made it an attractive partner for AWS, Dan Sheeran, AWS’ general manager of Healthcare & Life Science, told CNBC. Sheeran and Bischoff began outlining the collaboration between the two groups after meeting in London around nine months ago.
AWS also has an established presence in the health-care sector. The company offers more health- and life-sciences-specific services than any other cloud provider, according to a release, and it inked other high-profile AI partnerships with GE HealthCare, Philips and others last year.
The partnership between General Catalyst and AWS will stretch over several years, but new tools from Aidoc and Commure are coming in 2025. Aidoc is exploring how it can use the cloud to tap data modalities across pathology, cardiology, genomics and other molecular information, for instance.
Aidoc and Commure were selected to kick off the collaboration because they have both established a product-market fit, are operational and are focused on issues that are a high priority for AWS customers.
“GC has spent a lot of time thinking about how health systems can transform themselves, and we recognize that it’s not going to be through 1,000 companies, and we need solutions that are really enterprise grade,” Bischoff said. “Amazon shares the same vision, so we are starting with these two.”
Though the partnership between General Catalyst and AWS is still in its early days, the organizations said they believe it will help serve as a way to meet the market’s growing demand for new solutions.
“Health system leaders who want to realize the benefits of AI now have an easier way to accomplish that,” Sheeran said.